this article reviews the pertinent literature on the reported adverse reactions to bismuth compounds to provide the necessary background to assess the value of bismuth subcitrate and bismuth subsalicylate as therapeutic compounds .
C0106556
bismuth subcitrate
C0053792
bismuth subsalicylate